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Background: Many non-pharmacological treatments for children and adolescents with 
attention-deficit/hyperactivity disorder (ADHD) have been attempted, but reports indicate that 
most are ineffective. Although neurofeedback (NF) is a treatment approach for children with 
ADHD that remains promising, a variety of appropriate measures have been used in reporting 
and evaluating its effect. 
Objective: To report the self-evaluations of NF treatment by children and adolescents with 
ADHD. 
Methods: Randomized controlled trial in 91 children and adolescents with ADHD, aged less 
than 18 years (mean, 11.2 years) participated in a 30-session program of intensive NF treatment. 
Participants were randomized and allocated by sequentially numbered sealed envelopes into 
three groups: methylphenidate (MPH) as an active control group, and two trial groups NF with 
MPH, and NF alone. ADHD core symptoms and school performance were given on a scale 
of 1 to 10 using a self-reporting questionnaire, and the changes in these scores after treatment 
were used as the self-reported evaluation. Basic statistical methods (descriptive, analyses of 
variance, exact χ2 test, and paired t-test) were used to investigate the baseline data. Changes 
in ADHD core symptoms and treatment effects were investigated using a general linear model 
for repeated measures. 
Results: Eighty participants completed the treatment study and 73 (91%) responded sufficiently 
on the self-reporting questionnaires. The treatment groups were comparable in age, sex, and cog-
nition as well as in the baseline levels of core ADHD symptoms. All treatments resulted in sig-
nificant improvements regarding attention and hyperactivity (P0.001), and did not differ from 
each other in effectiveness. However, a significant treatment effect in school performance was 
observed (P=0.042), in which only the NF group showed a significant improvement.
Conclusion: The self-reported improvements in ADHD core symptoms and school performance 
shortly after treatment indicate NF treatment being promising in comparison with medication, 
suggesting NF as an alternative treatment for children and adolescents who do not respond to 
MPH, or who suffer side effects. Further long-term follow-up is needed.
Keywords: attention deficit/hyperactivity disorder (ADHD), neurofeedback (NF), self-report, 
randomized controlled trial (RCT)
Introduction
Attention-deficit/hyperactivity disorder (ADHD) is a serious health problem, and 
adequate multimodal treatment is necessary to avoid development of behavior prob-
lems, academic impairment, social dysfunction, and poor self-esteem.1 Almost one 
in four children do not respond sufficiently to central stimulation treatment,2 and 
ADHD symptoms can continue after psychopharmacological treatment has been 
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withdrawn.3 Alternative treatments are therefore continu-
ously being sought.
Recently, neurofeedback (NF) has been proposed as a 
treatment for ADHD that improves attention and decreases 
hyperactivity symptoms.4–8 NF is an electroencephalographic 
(EEG) operant-conditioning training technique that helps 
individuals to alter their brain activity.9 It is a kind of behav-
ioral therapy aimed at developing skills for self-regulation 
of cortical activity.10,11 This method uses real-time EEG 
displays to develop skills which regulate brain activity.11–13 
NF is aiming to normalize the EEG by improving cortical 
functioning.14 The patient learns to enhance the EEG desired 
frequencies and suppress the undesired ones in the form of 
a rewards system.15 This may affect for example attention, 
or other neurocognitive processes.16
In mostly uncontrolled and non-randomized studies NF 
has been shown to provide therapeutic benefits to patients 
with ADHD.7,8,17 A meta-analysis by Arns et al and Lofthouse 
et al reviewed randomized and non-randomized, published 
and unpublished trials and illustrated that some studies are 
limited by incomplete randomization (even randomized 
trials), small sample size, semi-active control groups, and 
no placebo and that more randomized, placebo control 
studies are needed.18,19 Lately, randomized studies from 
Duric et al and Meisel et al found promising evidence of 
ADHD symptom improvements in treatment with NF.20,21 
Significant improvements of ADHD symptoms over time 
after NF treatment were found in a double-blind placebo 
feedback-controlled design by Lansbergen et al.22 Recently, 
Sonuga-Barke et al suggested in a review of randomized 
controlled trials, alternative treatment of ADHD including 
NF and suggested that better evidence for efficacy of NF is 
required with blinded assessments.23
While NF has been reported to improve core ADHD 
symptoms, increase self-esteem,3,4,8 and improve learning,9 
the mechanism of action still remains unknown. However, 
it is important to explore the effect by self-reporting as well. 
For adults few self-report studies have indicated that NF is 
comparable to treatment with stimulant medication.24–26
Using self-report in studies of children and adolescents 
with ADHD has been poor, with inconsistent and divisive 
results.25,27 The validity of health-quality reports is much 
greater when individuals report their own perceptions.28 
The reliability of self-reports and the ability of teachers, 
parents, and key workers to assess ADHD symptoms have 
been questioned.26 Although parent reports differ from 
those of children, the child has valuable awareness of own 
experiences, especially for medical history, behavior, and 
health care.26,29 While some studies of children with ADHD 
suggest that despite functional problems in areas such as 
 academics and development, self-reports tend to under-report 
the presence of symptoms,30,31 other studies indicate that they 
describe their difficulties adequately.30,31 Among self-report 
studies, those that have used NF are virtually nonexistent, 
although reports from parents and teachers do exist.32
One of the most basic reasons for investing resources in 
child self-report health data is that parents appear as proxy 
respondents and their reports correlate poorly with those of 
their children, which is a reason often cited for not assess-
ing children directly. Despite the increasing acceptance of 
adolescents’ self-reports, their concordance with reports 
from their parents is not any better than that of parents and 
children.33,34 In the present study we wanted to explore self-
reported efficacy of NF treatment in a clinical, randomized, 
and controlled study of ADHD children and adolescents.
Methods
randomized controlled  
trial NcT01252446
Subjects and randomization
Children and adolescents with ADHD (aged under 18 years) 
who were diagnosed with ADHD according to the Interna-
tional Statistical Classification of Diseases and Related Health 
Problems Tenth Revision (ICD-10) at the Child and Adolescent 
Mental Health Clinic, Fonna Trust, Haugesund, Norway, from 
2007 to 2009, were invited to participate in the study.32,35,36 One 
hundred and thirty participants with ADHD were randomly 
assigned to one of three groups: 1) a group treated only with 
methylphenidate (MPH) defined as active control group, and 
two experimental groups; 2) a group treated with NF and 
MPH (NF/MPH group), and 3) a group treated with NF (NF 
group). Randomization was performed using a random list 
with arbitrary numbers (0-1-2) in order to make three groups. 
No stratification regarding age, sex, or IQ was done.
Cognitive performance was assessed before starting 
treatment using the Wechsler Intelligence Scale for Children 
Revised edition (WISC-R).37 Subjects in the MPH and NF/
MPH groups were administered MPH twice per day, at the 
recommended dose of 1 mg/kg, with total daily dosages 
ranging from 20 to 60 mg.
The Regional Ethics Committee on Medical Research 
approved the project protocol, and written consent was 
obtained from all of the children or parents.
aDhD
The population of Norwegian children who were referred for 
ADHD treatment during the 3 year period has been described 
in earlier publications.35,36 The children underwent  diagnostic 
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assessment to confirm the diagnosis of ADHD. In short, 
assessment included a clinical psychiatric interview and 
observations to assess ADHD and other appropriate diagnoses. 
Questionnaires regarding ADHD were filled out by the chil-
dren, parents, and teachers of the children. A medical examina-
tion was done to exclude somatic conditions causing ADHD 
symptoms. A child psychiatrist evaluated the assessments and 
categorized the children as having ADHD or a non-ADHD 
condition according to ICD-10 diagnostic criteria.38
Treatment groups
The 130 participants with confirmed consent were ran-
domly allocated by a coordinator into three groups: 1) the 
MED group, those treated with psychostimulant medication 
(MPH), 2) the NF + MED group, those treated with both 
NF and medication (MPH), and 3) the NF group, those only 
treated with NF.
Neurofeedback
Each participant was provided with 30 NF treatments for 
the duration of the study. Three sessions per week were 
conducted. The duration of each session was 45 minutes 
where each session started with 5 minutes of relaxation 
using alpha enhancement feedback, followed by two training 
sessions of twenty minutes each.
The system used for the recording was a Procomp Infinity 
from Thought Technology Ltd. (Montreal, QC, Canada) 
running Biograph Infinity software. This system is an eight 
channel, multi-modality encoder that is flexible, and designed 
for both clinical and research settings. The first two sensor 
channels provide ultimate signal fidelity (2,048 samples/s) 
for viewing raw EEG, electromyography (EMG), and electro-
cardiography (EKG) signals, and the remaining six channels 
(256 samples/s) can be used in combination with a variety of 
sensors such as EEG, EKG, EMG, skin conductance, heart rate, 
blood volume, pulse, and respiration. The system has an appli-
cation suite which is a grouping of screens, computations, and 
protocols to be custom tailored to a user’s particular needs.
The NF training was based on the standard theta/beta pro-
tocol in Cz for ADHD treatments from Lubar (Association 
for Applied Psychophysiology and Biofeedback).39,40 In 
this protocol beta activity (16–20 Hz) is enhanced and theta 
(4–7 Hz) is suppressed.
In order to attach the electrodes to the scalp and ensure 
minimum impedance skin preparation was done with conduc-
tive Nuprep EEG skin gel (Weaver and Company, Aurora, 
CO, USA).41 The electrode placement was at Cz (based on 
the 10–20 system of electrode placement) for all patients 
referenced to an ear (unipolar derivation). During the NF 
session, brain activity was shown to the participant using 
visual and auditory feedback.
For the training theta activity was defined as 4–7 Hz, beta 
activity as 15–20 Hz. EMG activity, defined as 80–150 Hz, 
was also monitored. The goal was to decrease theta activity by 
inhibiting high amplitude theta activity and by simultaneously 
rewarding high amplitude beta activity. Successful treatment 
was defined as a significant increase in beta activity, and a 
decrease in theta and EMG activities. Rewards were given if 
participants could keep theta levels below threshold 70% of 
the treatment time and keep beta levels above threshold 20% 
of the time. Depending on the participant’s performance these 
reward thresholds were manually adjusted by the therapist. 
In addition, the therapist verbally reinforced the participant’s 
performance and helped with progress.
After each session, the therapist and participant discussed 
the session in order to enhance motivation and engagement 
for further treatment.
self-reporting questionnaire (srQ)
Due to the nature of ADHD, the number of questions in an 
SRQ was limited to ensure that each child would be able to 
complete the questionnaire. So for this study we developed 
an SRQ, with questions derived from other questionnaires, 
including the Self-rating Scale of Self-regulatory Function27 
and the Piers-Harris Children’s Self-Concept Scale.42 The 
SRQ consisted of five single items, two concerning ADHD 
core symptoms (inattention, hyperactivity) and three regard-
ing school performance (mathematics, reading, and writing 
skills); school performance was defined as the sum of the 
three items (Supplementary materials).
The children were asked how they would rate themselves 
on a scale of 1–10 with regard to inattention, hyperactivity, 
and school performance. The SRQ was assessed at differ-
ent time points (T
1
, T
2
). The pre-treatment (T
1
) SRQ was 
assessed just before beginning the NF therapy, and the post-
treatment (T
2
) SRQ was completed approximately 1 week 
after completing the therapy. The self-reported evaluation of 
treatment was thus calculated as the change in score from 
period T
1
 to T
2
 (T
2
–T
1
).
statistical analyses
Basic statistical methods (descriptive, analyses of variance 
[ANOVA], exact χ2 test, paired t-test) were used to investi-
gate the baseline data.
The pre–post changes as well as the treatment effects 
were investigated using a general linear model (GLM) for 
repeated measures, which was implemented for each subscale 
(inattention, hyperactivity, and school  performance). The 
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model included the raw scores at both time points as dependent 
variables and the treatment groups as independent factors. 
In the GLM, we tested both pre–post changes in the ratings 
as well as treatment effects (differences between the treat-
ments). Significance of differences between the treatments 
was further examined using post hoc tests. Additionally, we 
estimated the standardized effect size ES δ
RM
 according to 
Morris and DeShon for each treatment change.43
The general significance level was set to 0.05. For the 
baseline investigation, we had to take into account the effects 
of multiple comparisons. However, we decided to set the 
significance level to 0.01, as a compromise between a Bonfer-
roni correction and not accounting for multiple comparisons. 
In the GLM, we investigated only highly correlated variables, 
thereby reducing the number of comparisons. Therefore, we 
did not adjust the significance level. A correlation between 
self-report and parents’ report was performed. All computa-
tions were done using SPSS 21 (IBM Corporation, Armonk, 
NY, USA).
Results
Subjects
Of 130 randomized participants 91 completed the treatment, 
but only 80 participants agreed to fill out the SRQ (Table 1). 
However, three did not answer the SRQ for attention and 
hyperactivity (questions 1 and 2), and a further four par-
ticipants did not complete the SRQ for school performance 
(question 3 to 5). The mean age for the 80 participants 
was 11.2±2.8 years, and the majority of participants were 
boys (81%).
Dropouts
After randomization of 130 participants, a total of 39 chil-
dren (30%) “dropped out” before or during the treatment.20 
Before treatment started 29 participants (ten, eleven, and 
eight patients from groups 1–3, respectively) “dropped out” 
due to parental lack of interest, loss of child/adolescent 
motivation, or other practical reasons such as difficulties and 
costs of transportation, family situation. During treatment, a 
further ten participants (three, three, and four patients from 
groups 1–3, respectively) “dropped out” with no reason 
given. For the 91 participants completing treatment, eleven 
participants did not complete the SRQ (four, four, and three 
from groups 1–3, respectively). Of these 80 participants 
who completed SRQ, three of them missed the question 
concerning ADHD core symptoms (77) and additionally 
four participants did not answer on school performance (73). 
However, post-randomization analyses found the balance for 
variables age, sex, IQ, comorbidity, and socio-demography 
between the “dropouts” and treatment groups.
Treatment groups
Baseline properties of the study sample are given in 
Table 1. None of the characteristics (age, sex, IQ, and 
ADHD symptoms) was significantly different between 
the treatment groups (P0.01), although differences in 
hyperactivity baseline scores almost reached significance 
(P=0.011). The three groups were comparable with regard 
to sociodemographic characteristics, including family 
constellation, siblings, parent education, economic factors, 
and other means of support such as child welfare and special 
school support.
evaluation of pre–post changes
Pre–post changes and results of the GLM estimation are 
given in Table 2. We found a significant improvement in 
SRQ score for both attention (P0.001) and hyperactivity 
(P=0.001) without adjustments. The effect sizes for all groups 
were positive. The significant pre–post changes disappeared 
after adjustment for age and sex.
For school achievement, the GLM analysis did not reveal 
any significant change in SRQ score after treatment (P=0.568, 
unadjusted). Note however, that school performance in the 
NF group did show a significant improvement (mean differ-
ence 1.5; 95% confidence interval [CI] 0.1 to 0.29).
evaluation of treatment effect
Treatment effect was defined as the score difference between 
the treatment groups. We observed a significant effect of 
treatment on school performance (P=0.04), but not for 
hyperactivity (P=0.9) or attention (P=0.7) using the unad-
justed model (Table 3). Similar results were obtained from 
the adjusted model. As seen in the results of the pre–post 
analysis, the NF group reported significant improvement in 
school performance (CI: NF, 0.1 to 2.9); the other groups did 
not (CI: MPH, -1.2 to 1.4; NF/MPH, -2.3 to 0.3).
School performance, tested by one-sample t-test (if the 
change score equals 0), increased for the NF group signifi-
cantly regarding writing (P=0.04) and calculation (P=0.05). 
The MED group reported a significantly increased perfor-
mance in calculation (P=0.03).
Correlation between the participants  
and parents
The two core symptoms of ADHD reported by parents were 
addressed in an earlier study.32 We did not find significant 
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Table 1 Comparisons between ADHD core symptoms, school performance, age, IQ, and sociodemographic characteristics between 
the three experimental groups before treatments began
 Total 
(N=80) 
mean (SD)
MPHa group 
(N=27) 
mean (SD)
NF/MPHa group 
(N=25) 
mean (SD)
NF group 
(N=28) 
mean (SD)
P-value
age (years) 11.2 (2.8) 10.9 (2.4) 11.2 (2.8) 11.4 (3.1) 0.770d
sex
Boys
iQ
65 (81%)
87 (14) 87 (15) 85 (13) 89 (14) 0.750d
aDhD core symptomsc
attention 5.0 (2.1) 5.4 (2.5) 5.0 (1.7) 4.6 (2.0) 0.370d
hyperactivity 5.0 (2.3) 5.1 (2.1) 6.0 (2.5) 4.2 (2.1) 0.011d
school performance 6.6 (2.8) 6.7 (2.6) 7.3 (2.7) 5.8 (2.8) 0.143d
Parents’ educationb 73 (91%) 0.951e
higher education (college or higher) 25 (34%) 8 (31%) 8 (38%) 9 (35%)
lower education 48 (66%) 18 (69%) 13 (62%) 17 (65%)
Parents’ employmentb 71 (89%) 0.101e
home 3 (4%) 2 (7%) 1 (6%) 0 (0%)
Unemployed 3 (4%) 2 (7%) 1 (6%) 0 (0%)
Part-time 12 (17%) 8 (30%) 1 (6%) 3 (12%)
Fulltime 53 (75%) 15 (56%) 15 (82%) 23 (88%)
income typeb 59 (73%) 0.184e
Fixed wage 43 (73%) 11 (58%) 13 (77%) 19 (83%)
Other 16 (27%) 8 (42%) 4 (23%) 4 (17%)
social functioningb 59 (73%) 0.754e
No/moderate problems 35 (59%) 15 (65%) 9 (53%) 11 (58%)
Severe problems 24 (41%) 8 (35%) 8 (47%) 8 (42%)
Siblingsb 61 (76%) 0.309e
2 siblings 32 (53%) 8 (38%) 10 (59%) 14 (61%)
2 siblings 29 (47%) 13 (62%) 7 (41%) 9 (39%)
child welfare supportb 73 (91%) 0.105e
No support 48 (66%) 14 (52%) 15 (83%) 19 (68%)
support 25 (34%) 13 (48%) 3 (17%) 9 (32%)
Notes: aMedication dosage: 1 mg/kg MPH, twice per day (total daily doses ranging from 20 to 60 mg); bN (%); cself report questionnaire, scale 1–10; daNOVa; eexact χ2-test.
Abbreviations: ANOVA, analyses of variance; ADHD, attention-deficit/hyperactivity disorder; NF, neurofeedback; MPH, methylphenidate; SD, standard deviation.
correlations between the reports from children and parents 
for any domain at a 5% level. The same pattern of correlation 
was found for both time points (T
1
 and T
2
).
Discussion
The present study randomly assigned ADHD children and 
adolescents to active control and two experimental groups 
evaluating NF with self-reports. Shortly after treatment par-
ticipants in all three groups reported improvement in ADHD 
core symptoms, with no significant differences in ADHD 
symptoms between the groups.
 Previous studies have seldom discussed self-reports in 
conjunction with NF treatment in young people with ADHD. 
While most studies have confirmed the difficulties in self-
report design studies, they also express the importance of 
self-reporting in ADHD children and adolescents.27,44–46 In 
addition, considerable variation has been observed depending 
on the type of questions used for assessment.47 In the present 
study we wanted to explore the changes from one time to 
another using the same questions for the same participant and 
therefore we found it reasonable to compose a short form to 
make sure that as many participants as possible were able 
to complete the SRQ. This was accomplished in the present 
study for more than four in five participants.32,48
Children reported similar effects in all three measured 
factors across the three treatment groups. Other studies have 
also reported that clinical improvements in core ADHD 
symptoms after NF and stimulant medication were on par 
with each other.8,49,50 Indeed, NF and MPH were correspond-
ingly effective in treating core ADHD symptoms in two sepa-
rate groups.7 However, no significant pre–post changes in any 
groups after adjusting for age and sex have been found. The 
lack of a significant difference after adjusting for confound-
ing factors was probably due to the small sample size, and a 
lack of power in the study with additional variables. Further, 
it is important to emphasize that the changes reported here 
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were evident only 1 week after treatment completion which 
can be a bias, thus, longer follow-up is needed.
NF effect in randomized studies demonstrated a lower 
effect size (ES) for hyperactivity, suggesting that hyperactiv-
ity is probably most sensitive to non-specific treatment factors 
(eg, time spent with a therapist), which is not in accordance 
with non-randomized studies.16,18,39,40,51–53 Moriyama et al 
concluded in a review that non-randomized controlled tri-
als found medium-to-large ESs, while the evidence for an 
NF effect in randomized controlled studies was considered 
more resilient.12 Still, there is no available data on optimal 
treatment protocols or to guide clinicians on predictors of 
NF response.
The impact of non-specific factors, such as parental 
support and/or cognitive training during NF treatment has 
been evaluated.18,54 Those studies concluded that the patient-
therapist interaction and the time spent with the therapist 
in a structured learning environment may contribute to a 
positive behavioral effect reported in NF treatment.54 NF 
sessions are thought to be a form of “cognitive training”, as 
the therapist and patient interact, meet regularly, and spend 
time together. Evaluation of cognitive training activities 
may have positive implications on NF treatment results, as 
they may support the learning process, augmenting results. 
Arns et al has suggested that hyperactivity could be more 
Table 3 characteristics of 130 randomized participants in 
the neurofeedback treatment study of ADHD children and 
adolescents
Completed 
(91) N (%)
Dropout 
(39) N (%)
sex – male 106 (82%) 24 (62%)
age* 11.5 [6–17] 12.0 [7–17]
Family (both parents) 49 (52%) 18 (46%)
Foster family 2 (5%) 15 (56%)
Two or more siblings 48 (58%) 18 (46%)
Father employed full time 45 (50%) 18 (46%)
Mother employed full time 42 (46%) 17 (45%)
cW support 5 (5%) 2 (5%)
Number of IQ-tested 70 (77%) 29 (74%)
Mean iQ, full scale* 87 [14] 89 [11]
Comorbidity
 – Total 73 (80%) 27 (69%)
 – ODD 49 (67%) 15 (56%)
 – anxiety 24 (33%) 12 (44%)
 – Others 12 (14%) 2 (7%)
Subtypes
 – Combined 72 (79%) 35 (90%)
 – hyperactivity 14 (4%) 3 (8%)
 – inattention 5 (5%) 1 (3%)
Notes: *Mean ± sD median [min, max].
Abbreviations: ADHD, attention-deficit/hyperactivity disorder; SD, standard deviation; 
CW, child welfare; ODD, oppositional-defiant disorder.
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easily influenced by non-specific effects than inattention and 
impulsivity.18 Moreover, parental support, including simply 
transporting participants to and from the place of treatment, 
is also of importance when evaluating the NF effect.
Reported levels of school performance were higher in 
the NF group, which seems to be in accordance with results 
reported by Gaddes and Edgell.55 They reported improve-
ments in academic performance in 80% of ADHD children 
who were treated with NF.55 Cognitive improvements in 
children with ADHD have been reported after NF treatment 
from Leins et al.57 Fernandez et al also found increased 
cognitive and academic/school performance in children with 
learning disabilities after the NF treatment and explained 
it as a consequence of changes in brain activity during the 
treatment.56 The effect of self-regulation on cognitive and 
academic performance has also been described by Strehl 
et al after NF treatment with SCP.48
It is interesting that NF alone, but not in combination 
with medication, influences school performance. The simple 
explanation may be personal and subjective perception of 
the effectiveness by making improvements in you alone 
and with own means and effort. Or, one can guess whether 
improved cognitive functions or the transferring of learn-
ing process which the child is exposed to during the treat-
ment, may influence or improve school performance. NF 
is a learning process to regulate one’s own brain activity.48 
Also, because it is a learning process, it has to be repeated 
in order to enhance the skills. School performance will 
improve once this has been achieved, and will most often 
be maintained.
However, influence of change in parental style throughout 
the NF treatment as well as parents’ expectations and sat-
isfaction with the treatment, such as reported by Leins et al 
might have affected the behavior and school performance 
and therefore confounded outcome variables.57
The strengths of the present study are the randomized 
design, use of ICD-10 diagnostics with a multi-domain 
diagnostic assessment, and a follow-up rate that is reasonable 
for ADHD studies. Previous studies have seldom included a 
control randomization, and therefore evidence of NF effect 
has been interpreted with precaution.8,19,22,47,48,58–60 As the 
randomization process is often demanding in order to fulfill 
all requirements, it often extends the study period.
A control group with stimulant medication was assigned 
in accordance with earlier studies.7,8,16 We also tried to estab-
lish a placebo control group using “sham” treat ment. During 
the pilot period, the NF sham placebo was found unfeasible 
due to difficulties for the therapist to adjust feedback 
parameters and placebo conditions. In addition, this placebo 
treatment was not ethically approved in the present thesis, 
which Logemann et al has also addressed.61
There is no well-established standard NF treatment 
protocol, which presented a challenge to this study. In 
Lofthouse et al’s62 review they found that two in three 
studies have used unipolar electrodes with a Cz placement 
equivalent to the present study.12,19 They found a variety 
of session numbers (20–40), and a variety of treatment 
durations (30–60 min), frequency (1–5 times/week), and 
course durations (2–20 weeks) for NF treatment in differ-
ent studies.8,16,62 To our knowledge, there is no existing 
consensus on standard methods regarding recommended 
number and frequency of sessions and standard placement 
of NF screening.19,62 Summarizing previous literature, 
30 sessions, three times per week for 11–13 weeks using 
Cz unipolar placement was regarded as a “recommended” 
protocol, and therefore used in the present study. Further-
more, it remains unclear whether the theta/beta protocol 
represents an “optimal” training protocol for ADHD 
patients or whether other NF protocols may prove more 
effective.
Conclusion
The present study indicated that children and adolescents with 
ADHD experienced effects of NF, reported after 1 week. NF 
seemed to be promising as an alternative treatment given that 
almost a third of all children diagnosed with ADHD have 
complications or side effects from medication. Furthermore, 
while many parents oppose stimulant-based treatments on 
principle, they are likely to approve of NF. Long-term studies 
are needed to confirm these results.
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Supplementary material
Self-report questionnaire (SRQ)
ID NR:
Self-report form for T1  T2  T3 
Answered by the patient in the scale of 1–10.
Scale 1–10: Comments: 
1. can you concentrate? (1= bad, 10= good) 
2. can you sit quietly? (1= bad, 10= good) 
3. What is your academic development at school? (1= bad, 10= good) 
how can you
– read
– Write
– calculate
(1= bad, 10= good) 
Notes: T1-period before the treatment, T2-1 week after the treatment, T3–6 months after the treatment.
N
eu
ro
ps
yc
hi
at
ric
 D
ise
as
e 
an
d 
Tr
ea
tm
en
t d
ow
nl
oa
de
d 
fro
m
 h
ttp
://
ww
w.
do
ve
pr
es
s.
co
m
/ b
y 
12
9.
17
7.
16
9.
20
 o
n 
09
-D
ec
-2
01
4
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                            10 / 10
